CAMKK2 and neoplasm: We find that deletion of CaMKK2 in myeloid cells, or its pharmacological inhibition, attenuates tumor growth in a CD8+ T cell-dependent manner, facilitating a favorable reprogramming of the immune cell microenvironment.